....is RVX in full lockdown and in wait for the world to open up again????,,,,seems one biotech is moving forward unhindered during this pandemic,,,,,, ???

Novartis business development stays on course during COVID-19
Having relied heavily on the expansion of external innovation through licensing, partnering and bolt-on acquisitions to build flexibility into the pipeline, Novartis is not shying away from its business development strategy despite Covid-19 causing disruption, reports BioCentury. Since the pandemic began, Novartis has already closed at least four deals with biotechs, including the latest acquisition of Amblyotech Inc